Protocol Ledger

NCT03127267 · Phase III · RECRUITING

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Interventional Phase III clinical trial protocol NCT03127267 sponsored by AB Science in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-02 Enrollment: 495 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03127267
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)495 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03127267
Protocol FieldVerified Registry Value
NCT IdentifierNCT03127267
Consolidated Lead SponsorAB Science
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment495 participants (ESTIMATED)
Registered Start Date2021-02-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI